• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search

    7/30/25 7:12:00 AM ET
    $LH
    Medical Specialities
    Health Care
    Get the next $LH alert in real time by email

    Test Finder interprets provider questions in context to deliver curated, clinically relevant results, going beyond traditional search

    Developed in collaboration with Amazon Web Services, Test Finder is now available on Labcorp.com

    BURLINGTON, N.C., July 30, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder, a first-of-its-kind generative AI tool developed with Amazon Web Services (AWS). Designed to simplify lab test selection, Test Finder enables healthcare providers to ask questions or describe conditions in plain language and receive curated test recommendations—enhancing the user experience and freeing up more time for patient care.

    Photo courtesy of Labcorp (PRNewsfoto/Labcorp)

    Laboratory testing plays a critical role in healthcare, informing nearly 70% of clinical decisions and often serving as the first step in diagnosing and managing patient conditions. Yet research shows providers spend more than three hours a day on responsibilities including documentation and test ordering—time that could be spent with patients. According to a recent American Medical Association (AMA) survey, 57% of physicians view addressing administrative burden through automation as the greatest opportunity for AI in healthcare.

    "Clinicians are under increasing pressure to do more with less," said Dr. Brian Caveney, Labcorp's chief medical and scientific officer. "Test Finder is designed to ease that burden by providing a faster, more intuitive way to navigate complex test menus, conduct research and identify the right tests, so clinicians can focus on what matters most: their patients."

    Key Features of Labcorp's Test Finder

    Now available on Labcorp.com, Test Finder was developed using Amazon Bedrock and large language model (LLM) technology. The tool enables providers to ask questions or describe conditions in plain language and receive a detailed list of suggested tests and descriptions based on their input. Additional benefits include:

    • Access to thousands of lab tests across key therapeutic areas, including oncology, women's health, neurology, autoimmune disease and more
    • Faster, more efficient navigation that reduces time spent on test selection
    • Available 24/7 on Labcorp.com

    "Labcorp's AI implementation underscores the transformative power of responsible generative AI in healthcare, setting a new industry standard for clinical workflow optimization," said Dr. Rowland Illing, global chief medical officer at AWS. "By leveraging AWS' enterprise-grade AI infrastructure and HIPAA-compliant security controls, Labcorp is revolutionizing how healthcare providers access comprehensive diagnostic information, enabling faster decisions that can directly impact patient care outcomes."

    "Test Finder is a powerful example of how we're using technology to simplify complexity," said Bola Oyegunwa, Ph.D., Labcorp's chief information and technology officer. "By integrating generative AI, we're not only improving the provider experience, we're laying the foundation for smarter, more connected healthcare solutions that scale with the needs of our customers."

    Labcorp anticipates sharing additional updates and announcements related to Test Finder in the coming weeks. For more information, visit www.labcorp.com.

    About Labcorp

    Labcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.

    Labcorp Logo (PRNewsfoto/Labcorp)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-introduces-test-finder-a-first-of-its-kind-generative-ai-tool-to-simplify-lab-test-search-302517300.html

    SOURCE Labcorp

    Get the next $LH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LH

    DatePrice TargetRatingAnalyst
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    4/2/2025$276.00Buy
    Redburn Atlantic
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    10/30/2024Hold → Buy
    HSBC Securities
    10/1/2024$235.00Neutral
    Piper Sandler
    3/25/2024$250.00Hold → Buy
    Argus
    More analyst ratings

    $LH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care

    Elecsys® pTau-181 test helps clinicians rule out Alzheimer's disease by identifying patients unlikely to have amyloid pathologyNow available nationwide in primary care settings for patients aged 55 and older experiencing symptoms of cognitive declineExpands Labcorp's comprehensive portfolio of Alzheimer's disease blood tests across both primary and specialty care settingsBURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessme

    2/11/26 7:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

    BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026. Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical r

    2/9/26 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026

    BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Partici

    1/15/26 4:15:00 PM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    SEC Filings

    View All

    SEC Form 144 filed by Labcorp Holdings Inc.

    144 - LABCORP HOLDINGS INC. (0000920148) (Subject)

    2/9/26 1:30:58 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    2/9/26 8:34:53 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    1/29/26 4:15:36 PM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Labcorp Holdings Inc. downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00

    7/10/25 9:03:30 AM ET
    $LH
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

    Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

    4/2/25 8:50:29 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. upgraded by Citigroup with a new price target

    Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously

    3/4/25 7:36:42 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Marketing Officer Summy Amy B. converted options into 230 shares and covered exercise/tax liability with 83 shares, increasing direct ownership by 3% to 5,722 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    2/13/26 1:19:13 PM ET
    $LH
    Medical Specialities
    Health Care

    SVP, Chief Accounting Officer Wilkinson Peter J converted options into 696 shares and covered exercise/tax liability with 206 shares, increasing direct ownership by 24% to 2,518 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    2/13/26 1:17:29 PM ET
    $LH
    Medical Specialities
    Health Care

    Chief Financial Officer, EVP Wang Julia Aijun covered exercise/tax liability with 245 shares and converted options into 860 shares, increasing direct ownership by 51% to 1,817 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    2/13/26 1:16:25 PM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Financials

    Live finance-specific insights

    View All

    Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026

    BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Partici

    1/15/26 4:15:00 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Declares Quarterly Dividend

    BURLINGTON, N.C., Jan. 14, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2026, to stockholders of record as of the close of business on February 27, 2026. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and c

    1/14/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp

    TOLEDO, Ohio, Jan. 8, 2026 /PRNewswire/ -- NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE:LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide. As a result of the acquisition, NAMSA assumes the U.S. portfolio of services of Labcorp's Ear

    1/8/26 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Laboratory Corporation of America Holdings (Amendment)

    SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

    2/13/24 5:08:06 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Laboratory Corporation of America Holdings (Amendment)

    SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)

    7/24/23 4:20:26 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

    2/10/21 11:14:27 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Leadership Updates

    Live Leadership Updates

    View All

    Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

    BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026. Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical r

    2/9/26 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Appoints Victor Bulto to Board of Directors

    Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025. Bulto is an accomplished global executive with 25 years of experience in healthcare, and a proven track record of leadin

    11/24/25 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

    ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as

    7/8/25 9:00:00 AM ET
    $LH
    $PRVA
    Medical Specialities
    Health Care
    Medical/Nursing Services